▎药明康德优于现有疗法！Moderna流感mRNA疫苗3期结果积极Moderna今日公布其季节性流感mRNA疫苗mRNA-1010在3期临床研究（P304）积极进展。该研究在50岁及以上的成人群体中评估了mRNA-1010相较于获批标准剂量季节性流感 ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Moderna 的季节性流感 mRNA 疫苗 mRNA-1010 在 III 期试验中展现出显著优势 —— 在 50 岁及以上人群中，其预防流感的效果比现有标准剂量疫苗高出 26.6%。这项覆盖 11 个国家、超 4 万名受试者的研究显示，65 岁以上老年人群的保护效力提升更为明显，达 27.4%。细分病毒株数据进一步验证其优势：对 A/H1N1 株保护效力提高 29.6%，A/H3N2 株提高 ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.